Literature DB >> 9290113

Recent developments in lipid emulsions: relevance to intensive care.

Y A Carpentier1, C Simoens, V Siderova, I el Nakadi, V Vanweyenberg, D Eggerickx, R J Deckelbaum.   

Abstract

For years, intravenous lipid supply has been considered as a means of providing an efficient fuel to many tissues of the body and of preventing or correcting essential fatty acid deficiency. The potential for lipid emulsions to modulate cell function via their content of specific fatty acids and of liposoluble vitamins has not received much attention yet. Soybean [long-chain triglycerides (LCT)] emulsions provide a valuable source of energy, but they are excessively rich in omega-6 essential fatty acids (FAs). Their infusion is associated with an accumulation of linoleate and a reduction of long-chain (> or = C20) omega-6 and omega-3 fatty acids in cell membrane phospholipids, as well as with a depletion of antioxidant status, associated with a reduction of alpha-tocopherol in plasma lipoproteins. Infusions of the mixed medium-chain triglycerides (MCT)/LCT (50%:50%; wt:wt) largely bypass these disadvantages. In addition, plasma elimination of MCT/LCT is faster than that of LCT. Recent advances indicate a great potential for omega-3 FAs incorporated into membrane phospholipids to modulate cell response to various stimuli and to influence several intracellular metabolic processes. Furthermore, some of these FA directly influence the production and the action of important mediators, the eicosanoids. In practical terms, an increased intake of omega-3 FAs may reduce inflammatory and thrombotic responses while protecting tissue microperfusion and immune defenses. Such properties may find interesting applications in several types of intensive care unit patients, provided that omega-3 FA incorporation takes place promptly. We recently had the opportunity to study in vitro and in vivo the metabolism of emulsions made of a mixture of MCT, soybean LCT, and fish oil triglycerides. Plasma elimination of such preparations appeared to be very fast, and their infusion was not associated with a prolonged residence of emulsion particles. In addition, uptake of remnants enriched with omega-3 FAs and liposoluble vitamins was fairly fast and occurred in several types of cells, leading to an efficient incorporation of omega-3 FAs in cell membranes within a few hours. The understanding that remnant uptake plays a significant role in the delivery of components included in lipid emulsions opens new areas of investigation and is likely to find several conditions of applications for new types of preparations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9290113     DOI: 10.1016/s0899-9007(97)00209-8

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  9 in total

1.  Lipid Emulsions Containing Medium Chain Triacylglycerols Blunt Bradykinin-Induced Endothelium-Dependent Relaxation in Porcine Coronary Artery Rings.

Authors:  Said Amissi; Julie Boisramé-Helms; Mélanie Burban; Sherzad K Rashid; Antonio J León-González; Cyril Auger; Florence Toti; Ferhat Meziani; Valérie B Schini-Kerth
Journal:  Lipids       Date:  2017-01-02       Impact factor: 1.880

2.  Tracking of the kinetic stability of 2 types of total nutrient admixtures containing different lipid emulsions.

Authors:  Judit Balogh; Dorottya Kiss; Judit Dredán; István Puskás; Ferenc Csempesz; Romána Zelkó
Journal:  AAPS PharmSciTech       Date:  2006       Impact factor: 3.246

3.  Novel Approaches for Omega-3 Fatty Acid Therapeutics: Chronic Versus Acute Administration to Protect Heart, Brain, and Spinal Cord.

Authors:  Hylde Zirpoli; Chuchun L Chang; Yvon A Carpentier; Adina T Michael-Titus; Vadim S Ten; Richard J Deckelbaum
Journal:  Annu Rev Nutr       Date:  2020-09-23       Impact factor: 11.848

4.  Optimization, and in vitro and in vivo evaluation of etomidate intravenous lipid emulsion.

Authors:  Dandan Geng; Yan Li; Chunyan Wang; Bo Ren; Heping Wang; Chensi Wu; Yirong Zhang; Linlin Zhao; Ligang Zhao
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

5.  Effects of an omega-3 fatty acid-enriched lipid emulsion on eicosanoid synthesis in acute respiratory distress syndrome (ARDS): A prospective, randomized, double-blind, parallel group study.

Authors:  Joan Sabater; Joan Ramon Masclans; Judit Sacanell; Pilar Chacon; Pilar Sabin; Mercè Planas
Journal:  Nutr Metab (Lond)       Date:  2011-04-08       Impact factor: 4.169

6.  Prospective double-blind randomized study on the efficacy and safety of an n-3 fatty acid enriched intravenous fat emulsion in postsurgical gastric and colorectal cancer patients.

Authors:  Cheng-Jen Ma; Jin-Ming Wu; Hsiang-Lin Tsai; Ching-Wen Huang; Chien-Yu Lu; Li-Chu Sun; Ying-Ling Shih; Chao-Wen Chen; Jui-Fen Chuang; Ming-Hsun Wu; Ming-Yang Wang; Ming-Tsan Lin; Jaw-Yuan Wang
Journal:  Nutr J       Date:  2015-01-21       Impact factor: 3.271

7.  Effects of perioperative supplementation with omega-3 fatty acids on leukotriene B₄ and leukotriene B₅ production by stimulated neutrophils in patients with colorectal cancer: a randomized, placebo-controlled intervention trial.

Authors:  Lone S Sorensen; Ole Thorlacius-Ussing; Henrik H Rasmussen; Søren Lundbye-Christensen; Philip C Calder; Karen Lindorff-Larsen; Erik B Schmidt
Journal:  Nutrients       Date:  2014-09-29       Impact factor: 5.717

8.  Impact of Intravenous Omega-3-Enriched Lipid Emulsion on Liver Enzyme and Triglyceride Serum Levels of Children Undergoing Gastrointestinal Surgery.

Authors:  Meta Herdiana Hanindita; Nur Aisiyah Widjaja; Roedi Irawan; Boerhan Hidayat; Igb Adria Hariastawa
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2020-01-08

9.  Effects on hemodynamics and gas exchange of omega-3 fatty acid-enriched lipid emulsion in acute respiratory distress syndrome (ARDS): a prospective, randomized, double-blind, parallel group study.

Authors:  Joan Sabater; Joan Ramon Masclans; Judit Sacanell; Pilar Chacon; Pilar Sabin; Merce Planas
Journal:  Lipids Health Dis       Date:  2008-10-23       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.